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myloid-
 
 
 
 peptide (A
 
 
 
) aggregate in senile plaque is
a key characteristic of Alzheimer’s disease (AD).
Here, we show that phosphorylation of amyloid
precursor protein (APP) on threonine 668 (P-APP) may play a
role in APP metabolism. In AD brains, P-APP accumulates in
large vesicular structures in afﬂicted hippocampal pyramidal
neurons that costain with antibodies against endosome
markers and the 
 
 
 
-secretase, BACE1. Western blot analy-
sis reveals increased levels of T668-phosphorylated APP
COOH-terminal fragments in hippocampal lysates from
many AD but not control subjects. Importantly, P-APP
A
 
cofractionates with endosome markers and BACE1 in an
iodixanol gradient and displays extensive colocalization
with BACE1 in rat primary cortical neurons. Furthermore,
APP COOH-terminal fragments generated by BACE1 are
preferentially phosphorylated on T668 verses those produced
by 
 
 
 
-secretase. The production of A
 
 
 
 is signiﬁcantly reduced
when phosphorylation of T668 is either abolished by
mutation or inhibited by T668 kinase inhibitors. Together,
these results suggest that T668 phosphorylation may facilitate
the BACE1 cleavage of APP to increase A
 
 
 
 generation.
 
Introduction
 
Extracellular deposition of amyloid-
 
 
 
 peptide (A
 
 
 
) aggregates
in the brain represents a defining pathologic feature of Alz-
heimer’s disease (AD; Price et al., 1995). A
 
 
 
 is derived from
proteolytic cleavage of amyloid precursor protein (APP), a
type I transmembrane glycoprotein that belongs to a protein
family that also includes APP-like protein (APLP) 1 and 2.
Either 
 
 
 
- or 
 
 
 
-secretase initiates APP processing by cleaving
the extracellular/lumenal domain, generating soluble NH
 
2
 
-
terminal fragments, sAPP
 
 
 
 or sAPP
 
 
 
, and a membrane-
anchored 83-residue or 99/89-residue COOH-terminal frag-
ments (
 
 
 
CTFs or 
 
 
 
CTFs), respectively (De Strooper and
Annaert, 2000). Subsequently, the membrane-bound frag-
ments are cleaved by 
 
 
 
-secretase in the transmembrane re-
gion, resulting in the production of p3 (from 
 
 
 
CTFs) or the
amyloidogenic peptides A
 
 
 
40 or A
 
 
 
42 (from 
 
 
 
CTFs).
Pharmacological and biochemical studies have shown that
 
 
 
- and 
 
 
 
-secretases are aspartyl proteases (Wolfe et al., 1999;
Yan et al., 1999). 
 
 
 
-Secretase (BACE 1) and its homologue
BACE2 are type I integral membrane glycoproteins (Sinha
et al., 1999; Vassar et al., 1999; Yan et al., 1999). BACE1
constitutes the primary 
 
 
 
-secretase activity in the brain
and is primarily localized within the Golgi and endosomal
compartments where the acidic pH is optimal for secretase
activities. To date, there is no known genetic linkage between
mutations in BACE genes and AD. However, BACE1
proteins and activities have been found to be increased in
AD brain regions affected by amyloid deposition, suggesting
its role in AD pathogenesis (Fukumoto et al., 2002; Holsinger
et al., 2002; Yang et al., 2003).
Presenilin proteins (PS1 and PS2) are integral components
 
of the 
 
 
 
-secretase directly responsible for the activity of
 
 
 
-secretase (Steiner and Haass, 2000). Importantly, missense
mutations within PS genes are associated with familial forms
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of AD. These mutations result in increased production of
A
 
 
 
42
 
,
 
 accelerating the formation of senile plaques (Hardy and
Crook, 2001). PS proteins are mostly localized in the endo-
plasmic reticulum, Golgi apparatus (Kovacs et al., 1996; De
Strooper et al., 1997), and endosomes (Lah and Levey, 2000).
A
 
 
 
 has been shown to be generated in both the secretory
and endocytic pathways of transfected cell lines and cultured
neurons (Selkoe et al., 1996; Perez et al., 1999; Nixon et al.,
2000). It is thought that A
 
 
 
 can first be generated in the
TGN. Remaining unprocessed APP is then transported to
the cell surface where it is either cleaved by the nonamy-
loidogenic 
 
 
 
-secretase or reinternalized into the endosomes,
where A
 
 
 
 generation has also been found. Disturbances in
neuronal endocytic pathway are among the earliest known
intracellular changes occurring in sporadic AD (Nixon et al.,
2000). In hippocampal neurons of these AD patients, endo-
somes are abnormally enlarged; a change that may precede
clinical symptoms, appearing before substantial A
 
 
 
 accumu-
lation. As such, abnormalities associated with the endocytic
pathway have been postulated to play a significant role in
amyloidogenesis (Cataldo et al., 2000).
How APP is targeted to the subcellular compartments con-
taining its processing enzymes remains to be elucidated. Sub-
cellular APP trafficking may be regulated by its phosphoryla-
tion. APP contains eight potential phosphorylation sites in its
cytoplasmic domain. Low level phosphorylation of T654 and
S655 (human APP695 isoform numbering) has been found
in rat brain (Oishi et al., 1997). These two amino acids are
part of the 
 
653
 
YTSI
 
656
 
 motif, which acts as an endocytic and/
or basolateral sorting signal, YXXI, in MDCK cells (Lai et al.,
1998; Zheng et al., 1998). Tyrosine kinases, TrkA and c-Abl,
have been shown to phosphorylate Y682 in vitro (Tarr et al.,
2002). The 
 
682
 
YENPTY
 
687
 
 motif is a canonical endocytic sig-
nal for membrane-associated receptors and mutations of
Y682, N684, or P685 have been shown to inhibit the inter-
nalization of APP and decrease the generation of secreted
sAPP and A
 
 
 
 (Perez et al., 1999; Steinhilb et al., 2002).
Threonine 668 (T668) in the cytoplasmic domain of APP
is also phosphorylated in vivo by a number of protein kinases,
including GSK3
 
 
 
, SAPK1b/JNK3, Cdc2, and Cdk5 (Suzuki
et al., 1994; Aplin et al., 1996; Iijima et al., 2000; Standen et
al., 2001). Many of these kinases are associated with neuro-
toxicity and implicated in neurodegenerative diseases. A solu-
tion NMR study suggests that T668 phosphorylation results
in significant conformational change that may affect the in-
teractions of APP with its binding partners (Ramelot and
Nicholson, 2001). As such, this phosphorylation may serve to
regulate the intracellular trafficking and metabolism of APP.
Here, we provide evidence that T668 phosphorylated APP
is significantly increased in AD brains. APP phosphorylated
on threonine 668 (P-APP) and BACE1 colocalize in en-
larged endosomes of AD hippocampal neurons and cultured
primary cortical neurons. P-APP and BACE1 from mouse
brain homogenates cofractionate in iodixanol gradients. Mu-
tation of T668 to alanine (T668A) decreases this cofraction-
ation. Furthermore, the COOH-terminal fragments of APP
generated by BACE1 cleavage, 
 
 
 
CTFs (C99/C89), are
preferentially phosphorylated over the 
 
 
 
-secretase cleavage
product, 
 
 
 
CTF (C83). Accordingly, A
 
 
 
 generation is sig-
nificantly reduced by mutation of T668 to alanine or by
 
treatment using T668 kinase inhibitors. Together, these ob-
servations suggest that T668 phosphorylation may facilitate
 
 
 
-secretase cleavage of APP and generation of A
 
 
 
 peptides.
 
Results
 
T668 phosphorylation is up-regulated in AD brains
 
To investigate P-APP in normal and disease brain samples, we
generated a rabbit polyclonal antibody against a phospho-
T668 containing peptide (
 
 
 
P-T668). We carefully charac-
terized these antibodies and confirmed that the 
 
 
 
P-T668
specifically recognized P-APP in vitro and in rat brain ly-
sates (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200301115/DC1). Next, we used 
 
 
 
P-T668 for im-
munohistochemistry to determine the T668 phosphorylation
status of APP in AD brain samples (case information in Ta-
ble S1, available at http://www.jcb.org/cgi/content/full/
jcb.200301115/DC1). The overall staining patterns of
P-APP in age-matched control and AD brains differed mark-
edly (Fig. 1, A–E). Intense staining was observed in AD hip-
pocampal pyramidal neurons (Fig. 1, B and D). Pre-adsorp-
tion of the antibody with the P-T668 containing peptide, but
not the unphosphorylated peptide, completely eliminated the
staining (Fig. S2, A–C, available at http://www.jcb.org/cgi/
content/full/jcb.200301115/DC1). Alkaline phosphatase
pretreatment of AD hippocampal sections abolished 
 
 
 
P-
T688 staining (Fig. S2, Da and b). Both mammalian APP
homologues, APLP1 and APLP2 contain a homologous
phosphorylated threonine in their cytoplasmic domains. Pre-
adsorption of 
 
 
 
P-T668 with phosphorylated APLP1 or
APLP2 peptides containing these sites did not affect the stain-
ing pattern produced by this antibody (Fig. S2, Ea–d) making
it unlikely that the 
 
 
 
P-T668 staining in AD brains was due to
phosphorylation of APLP1 or APLP2. Together, these results
indicate that the 
 
 
 
P-T668 specifically labels structures con-
taining T668 phosphorylated APP in AD brains.
We have examined the localization of P-APP in a total of 24
AD and 11 nondemented age-matched control cases. In gen-
eral, two structures that displayed strong P-T668 staining were
large, vesicular bodies within the cell soma of hippocampal
neurons (Fig. 1 D) and dystrophic neurites associated with
amyloid plaques (Fig. 1, E–I). We also determined the distri-
bution of P-APP in the brains of 18 mo-old APPsw Tg mice
and found that 
 
 
 
P-T668 labeled dystrophic neurites that are
closely associated with amyloid plaques (Fig. S2, F–I). How-
ever, no vesicular staining in the cell body is observed. Thus, in
the mouse model for amyloid plaques, P-APP is only present
in one of the two compartments where it is enriched in AD.
 
T668 phosphorylated APP accumulates in neurons 
positive for phospho-Tau
 
Double immunostaining of P-APP and phospho-Tau (AT8)
revealed a high coincidence of staining within neurons from
AD (Fig. 1 J). Among 1,373 neurons surveyed that were pos-
itive for P-T668, AT8 or both, 81% were double positive,
3% were only positive for P-T668 and 16% were only posi-
tive for AT8. Of the neurons positive for AT8 only, most
represented extracellular tangles that were remnants of degen-
erated neurons. This observation indicates that afflicted neu-
rons in AD exhibit increased levels of P-APP. AlthoughT
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P-APP and phospho-Tau were present in the same neurons,
they exhibited distinct subcellular localization; P-APP was
present in vesicular compartments, whereas phospho-Tau
was associated with filamentous structures (Fig. 1 K).
 
Phosphorylation of COOH-terminal fragments 
of APP in AD brains
 
To further investigate the phosphorylation of T668 in AD, we
performed Western blot analysis on hippocampal tissues from
14 AD and 10 age-matched control brains (Fig. 2 A; case in-
formation in Table S2, available at http://www.jcb.org/cgi/
content/full/jcb.200301115/DC1). No significant difference
in levels of P-T668 on full-length APP was observed between
AD and control brains. However, we found P-T668 on the
APP CTFs to be considerably increased in 8 of 14 AD brains.
To determine phosphorylation sites of APP CTFs, in ad-
dition to T668, we immunoprecipitated APP from AD hip-
pocampal lysates using 
 
 
 
P-T668, resolved and trypsin di-
gested the APP CTFs in a SDS-PAGE, and analyzed the
tryptic fragments using MALDI-TOF mass spectrometry
(MS). A summary of recovered peptides and a representative
MS spectrum of tryptic digests are shown in Fig. 2 (B and
C). The recovered peptides spanned the entire APP 
 
 
 
CTF
region. The presence of peptides 596–612, 596–624, 602–
Figure 1. T668 phosphorylated APP is elevated in human 
AD brains. (A) Age-matched control hippocampal section 
stained with  P-T668. (B) AD hippocampal section stained 
with  P-T668. Strong immunoreactivity is detected in 
pyramidal neurons and some plaque structures in the CA 
fields. (C–E) Higher magnification view of hippocampal 
sections. (C) Age-matched control brain. (D) Pyramidal 
neurons containing enlarged vesicular structures positive 
for P-T668. (E) P-T668–positive dystrophic neurites. 
(F–I)  P-T668 labels dystrophic neurites that are closely 
associated with amyloid plaques in AD brains. (F and H) 
R1282 (an A  antibody) staining of AD hippocampal 
section showing the distribution of amyloid plaques. 
(G and I) Adjacent section stained with  P-T668 antibody 
showing P-T668–positive dystrophic neurites surrounding 
the plaques. (J and K) DeltaVision deconvolution images 
showing staining of P-APP and phospho-Tau (AT8) on AD 
brain sections. P-APP is enriched in the same neurons 
that have increased phospho-Tau staining. Bars: (A and B) 
500  m; (C–E) 15  m; (F and G) 250  m; (J) 20  m; and 
(H, I, and K) 5  m.T
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612 and 602–624 indicated the existence of 
 
 
 
CTF (C99).
However, as trypsin also cleaves at the 
 
 
 
-secretase site, we
cannot rule out the presence of 
 
 
 
CTF or other species of
APP CTFs in the MS samples. Treatment of samples with
alkaline phosphatase before MS analysis significantly re-
duced the intensities of the phospho-peptide signals and re-
sulted in new ion peaks appearing at m/z positions repre-
senting dephosphorylated peptides, confirming that these
peptides were indeed phosphorylated (unpublished data).
Interestingly, we found that peptides spanning residues
650–672 and 651–672 contained three phosphates per pep-
tide. Peptides 652–676 and 673–695 contained four phos-
phates per peptide (Fig. 2 C). The sequence composition of
the peptide ion with m/z 3123 (peptide 652–676) was se-
lected and analyzed by postsource decay MS. We found that
Y653, S655, and T668 were phosphorylated, based on the
presence of corresponding y-ions and a phospho-tyrosine
immonium ion (unpublished data). Furthermore, the recov-
ery of peptide 673–695 with four phosphates suggested that
all potential sites (S675, Y682, T686, and Y687) were phos-
phorylated (Fig. 2 C). These results indicate that in AD
brains, APP CTFs contain at least seven different sites that
can be phosphorylated, including T668. As a control, we iso-
lated APP CTFs from neuroblastoma CAD cells overexpress-
ing human APP using an APP COOH-terminal antibody.
We found two phospho-peptides (peptides 651–672 and
650–672) containing three phosphates per peptide, indicat-
ing that three out of four potential sites (Y653, T654, S655,
Figure 2. The CTFs of T668 phosphorylated APP is elevated in AD brains. (A) Western blots of brain lysates from control and AD hippocampal 
tissues probed with  P-T668 or an antibody against the COOH terminus of APP (C1/6.1). (B) Schematic diagram of peptides detected by mass 
spectrometric analysis. APP immunoprecipitated by  P-T668 from AD brain tissue was separated on SDS-PAGE, digested with trypsin, and 
analyzed by MALDI-TOF MS. Identified peptides are illustrated. The numbering of residues is based on APP695. The phosphorylated residues 
in the cytoplasmic domain of APP are in bold. (C) A partial MS spectrum showing hyperphosphorylation of the COOH terminus of APP. MS 
peaks representing phosphorylated tryptic peptides derived from APP are indicated (arrows).T
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and T668) were phosphorylated. We did not detect any sig-
nal representing peptide 673–695, which contained four po-
tential phosphorylation sites (S675, Y682, T686, and Y687;
see Fig. S3, available at http://www.jcb.org/cgi/content/full/
jcb.200301115/DC1). This result showed that analogous
phospho-peptides of APP CTFs detected in AD brain sam-
ples were also present in recombinant APP expressing CAD
cells. Moreover, as many potential sites were not phosphory-
lated in APP expressing cells, it supports the notion that the
cytoplasmic domain of APP is hyperphosphorylated in AD.
Because the phosphorylated residues include serines, threo-
nines and tyrosines, this observation suggests that multiple
protein kinases are involved in APP phosphorylation in AD.
 
T668 phosphorylated APP is enriched in endocytic 
compartments and colocalized with BACE1 
in AD brains
 
The large vesicular structures positive for P-APP have not
been described previously (Fig. 1 D). To determine the nature
of this structure, we performed double immunofluorescence
staining on AD hippocampal sections with a large panel of or-
ganelle markers. As 
 
 
 
P-T668 recognizes both full-length APP
and APP CTFs, immunostaining using this antibody repre-
sents localization of both forms of APP phosphorylated on
T668. We found that P-APP–positive vesicles could be la-
beled by the endosome markers Rab4 (Fig. 3 A), Rab5 (Fig. 3
B), and EEA1 (Fig. 3 C), but not by the lysosome markers ca-
thepsin D (Fig. 3 D) or cathepsin B (Fig. S4 A, available
at http://www.jcb.org/cgi/content/full/jcb.200301115/DC1),
the synaptic vesicle marker SV2 (not depicted), the Golgi
markers GM130 or MannII (not depicted), or the ER mark-
ers Bip/Grp78 (not depicted) or GP96 (Fig. S4 B). These co-
staining results indicate that P-APP is enriched in the en-
docytic compartments of AD hippocampal neurons.
We also examined the presence of APP processing en-
zymes in the P-APP–positive vesicles. Interestingly, the
staining of 
 
 
 
-secretase BACE1 was robust in the P-APP–
positive neurons. Furthermore, BACE1 displayed extensive
colocalization with P-APP (Fig. 3 E). A second BACE1 anti-
Figure 3. Subcellular localization of P-APP in AD 
brain sections. (A–D) P-APP is localized to endocytic 
compartments but not lysosomes in AD brains. T668 
phosphorylated APP colocalizes with endocytic vesicle 
markers: (A) Rab4, (B) Rab5, and (C) EEA1, but not with 
the lysosome marker, (D) cathepsin D. (E) Colocalization 
of T668 phosphorylated APP and BACE1 in the enlarged 
vesicles in AD brains. Bars, 5  m.T
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body gave rise to similar staining pattern in AD brain sec-
tions (unpublished data). Antibodies to PS1 did not specifi-
cally label the P-APP–positive vesicles in AD brain sections
(unpublished data). These data suggest that P-APP colocal-
izes with BACE1 in enlarged endosomes in AD brains.
 
Colocalization of T668 phosphorylated APP and 
BACE1 in primary neurons
 
To further determine the subcellular distribution of
P-APP and its physiological relationship with BACE1, we
performed double immunostaining on normal rat primary
cortical neurons. In these neurons, P-APP signal appeared
punctate in the soma and growth cones with a distribu-
tion pattern somewhat distinct from that of regular APP
(Fig. 4, A and B). Interestingly, P-APP showed substantial
colocalization with the early endosome marker Rab5 in
the growth cones (Fig. 4, C and D). Modest overlap be-
tween P-APP and EEA1 (early endosome marker; Fig. 4
E), Rab4 (recycling endosome marker; Fig. 4 F), Rab7
(late endosome marker; Fig. 4 G) or adaptin-
 
 
 
 (TGN
marker; Fig. S5 A, available at http://www.jcb.org/cgi/
content/full/jcb.200301115/DC1) was observed. There was
little colocalization between GM130 (cis-Golgi marker;
Fig. S5 B) and P-APP. Interestingly, P-APP and BACE1
displayed extensive colocalization in the growth cones of
young neurons (Fig. 5, A and B) and showed partial
colocalization in neurites of 10-d-old cultured neurons
(Fig. S5, C and D). Only limited colocalization of regular
APP and BACE1 was observed (Fig. 5 C). P-APP and
PS1 also showed little colocalization in the growth cones
(Fig. 5 D).
We further performed immunoisolation experiments to
characterize P-APP, APP, and BACE1 containing vesicles
(Fig. 5 E). We found that Rab5 was present in P-APP, APP,
and BACE1 immunoisolates. Previous studies have shown
that APP is present in the TGN (Annaert et al., 1999).
However, we did not detect GM130 in any of the immu-
noisolates. In addition, the levels of BACE1 in P-APP
immunoisolates were higher than those in APP immuno-
isolates, indicating that T668 phosphorylated APP pref-
erentially colocalized with BACE1. Together, these ex-
periments suggest that P-APP is in the same subcellular
Figure 4. Subcellular localization of P-APP in cultured 
primary cortical neurons. Double immunofluorescence 
staining of rat primary cortical neurons. (A and B) Costaining 
of P-APP and regular APP (C1/6.1) in the (A) soma and 
(B) growth cone. (C and D) Colocalization of P-APP and 
Rab5 in the growth cones. (E–G) Costaining of P-APP and 
(E) early endosome marker EEA1, (F) recycling endosome 
marker Rab4, and (G) late endosome marker Rab7. 
Bars, 5  m.T
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compartment as the APP processing enzyme BACE1, in
both AD brains and cultured neurons.
 
T668 phosphorylated APP cofractionates with BACE1 
and endosome markers in an iodixanol step gradient
 
Next, we performed biochemical fractionations to gain ad-
ditional insight into the subcellular localization of P-APP.
Organelles in an adult wild-type mouse brain were sepa-
rated through an iodixanol step gradient (Fig. 6 A). West-
ern blot analysis using the APP COOH-terminal antibody
showed that full-length APP had a broad distribution be-
tween fractions 8–20. Full-length P-APP displayed a more
restricted profile between fractions 8–16. We also detected
P-APP signal in the bottom of the gradient (fractions 21–
23). As the gradient was bottom loaded, this likely repre-
sented unsegregated lysates, or possibly, the presence of
immature, less glycosylated P-APP in the early secretory
pathway. P-APP CTFs had a very discrete distribution
spanning fractions 9–13, whereas APP CTFs were present
between fractions 8–16. The APP CTFs detected by the
 
 
 
P-T668 displayed a higher molecular size than those de-
tected by the APP COOH-terminal antibody, indicating
that   P-T668 might preferentially label the  -secretase
product(s) of APP.
Organelle markers revealed that Rab5 displayed a broad
distribution, which overlapped with P-APP. Lysosomes, as
identified by cathepsin D, also displayed a broad distribu-
tion, which was shifted to the right of the gradient. The
Golgi apparatus (GM130) and ER (Bip) segregated to the
bottom of the gradient. Digitalization and plotting of the
Western blot signals of fractions 1–20 revealed that full-
length APP, P-APP and BACE1 largely cosegregated in
fractions 8–13 of iodixanol gradient with the APP signal
extended to the heavier fractions of the gradient (Fig. 6 B).
To assess the significance of T668 phosphorylation in APP
subcellular localization, we introduced wild-type and T668A
mutant APP into primary cortical neurons using recombi-
nant herpes simplex virus (HSV). 20 h after infection, cell
homogenates were fractionated through iodixanol step gradi-
ent and the distribution of APP was analyzed. Interestingly,
wild-type APP exhibited more extensive cosegregation with
BACE1 than the T668A mutant APP, which was shifted to
the heavier fractions of the gradient (Fig. 6 C; immunoblots
in Fig. S6 A, available at http://www.jcb.org/cgi/content/
Figure 5. T668 phosphorylated APP colocalizes with 
BACE1 in primary cortical neurons. (A and B) Costaining 
of P-APP and BACE1 in the growth cones. (C) Costaining 
of regular APP (C1/6.1) and BACE1 in the growth cone. 
(D) Costaining of P-APP and Presenilin 1(PS1) in the 
growth cone. Bars, 5  m. (E) Immunoisolation of P-APP, 
APP, and BACE1 containing vesicles. Vesicular organelles 
were immunoisolated from mouse brain homogenates 
using M-280 Dynabeads conjugated to anti–P-T668, 
anti-APP, or anti-BACE1 antibodies. Immunoisolates were 
examined by Western blot analysis.T
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full/jcb.200301115/DC1). T668 of APP can be phosphory-
lated by multiple kinases including Cdc2 and Cdk5. The ac-
tivities of these Cdks can be inhibited by pharmacological re-
agents roscovitine and butyrolactone. We analyzed APP
distribution from roscovitine treated cortical neurons by
fractionation using iodixanol gradient. Similarly, we found
that APP distribution shifted to heavier membrane fractions
after roscovitine treatment (Fig. 6 D; immunoblots in Fig.
S6 B). This observation indicates that T668 phosphorylation
plays a role in the intracellular trafficking of APP.
APP CTFs generated by  -secretase are preferentially 
phosphorylated on T668
To further determine the species of APP CTFs that is phos-
phorylated on T668 in vivo, we performed immunodeple-
tion experiments. We used CTFs derived from CAD cells
overexpressing C99, a  -secretase products of APP, as mark-
ers for identifying different CTF species (Fig. 7, A and B,
lane 1). We found that CTFs from mouse brain lysates gen-
erally showed slower mobility than those from C99 overex-
pressing CAD cells, possibly due to differences in the stoi-
chiometry of phosphorylation. As such, we assigned those
CTFs with slower mobility than C99 from CAD cells as
 CTFs and those with faster mobility than C89 as  CTFs.
In these brain lysates,  CTFs were much more abundant
than  CTFs (Fig. 7, A and B, bottom). Increasing amounts
of   P-T668 efficiently immunoprecipitated  CTFs, as
recognized by the APP COOH-terminal antibody, in a
dose-dependent manner (Fig. 7 A, top). A corresponding
dose-dependent decrease in  CTFs was observed in the su-
pernatant of these immunoprecipitates (Fig. 7 A, bottom).
On the other hand, the level of  CTFs in the supernatants
only decreased slightly. When 10  g of  P-T668 was used,
 60% of  CTFs were depleted, whereas only  10% of
 CTFs were depleted from the brain lysates (Fig. 7 C). As a
control, we used the APP COOH-terminal antibody to im-
munoprecipitate APP CTFs from mouse brain lysates. This
antibody efficiently removed both  CTFs and  CTFs from
the lysates (Fig. 7, B and C). These observations suggest that
the  -secretase products of APP are preferentially phosphor-
ylated on T668 in vivo and raise the possibility that T668
phosphorylation may facilitate APP cleavage by BACE1.
Effects of T668 phosphorylation on A  generation in 
primary cortical neurons
To elucidate whether T668 phosphorylation plays a role in
A  generation, we assessed A  levels from the cultured media
of neurons treated with the Cdk inhibitors roscovitine or bu-
Figure 6. T668 phosphorylated APP cofractionates with BACE1 and endosome markers. (A) Adult mouse brain homogenates were 
fractionated through an iodixanol step gradient. Western blot analysis showed the distribution of P-APP, APP, Rab5 (early endosome marker), 
cathepsin D (lysosome marker), GM130 (Golgi marker), Bip (ER marker), and BACE1. (B) Quantification of protein distribution of A (fractions 
1–20), showing that full-length P-APP largely cofractionates with BACE1. (C) Distribution of wild-type and T668A mutant APP, expressed in 
rat primary cortical neurons using recombinant HSV in an iodixanol step gradient. Note that the distribution pattern of BACE1 resembles that 
of wild-type APP. (D) Distribution of wild-type APP in an iodixanol step gradient after roscovitine treatment (15  M for 8 h). APP distribution 
shifted to heavier membrane fractions after roscovitine treatment.T
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tyrolactone. Because the levels of secreted A  from endoge-
nous APP was too low to be detected, we used recombinant
HSV to express wild-type APP in rat cortical neurons. Both
roscovitine and butyrolactone treatments caused substantial
decreases in T668 phosphorylation (Fig. 8 B). Interestingly,
levels of secreted A  1-40 and 1-42 were significantly reduced
by these inhibitors in a dose-dependent manner (Fig. 8 A).
The reduction in A  secretion was not due to a decline in cell
viability as determined by the MTT assay (unpublished data).
Butyrolactone and roscovitine are general Cdk inhibi-
tors. Because Cdks phosphorylate many substrates, it is
possible that the reduction in A  secretion is an indirect
effect resulting from reduced phosphorylation of proteins
other than APP. To directly test the hypothesis that T668
phosphorylation is involved in the metabolism of APP, we
compared A  levels generated from neurons expressing
wild-type versus T668A mutant APP. Rat cortical neurons
2 d in vitro were infected with HSV expressing either wild-
type or the T668A mutant APP. The A  levels in the cul-
ture media were determined 20 h after infection. Fig. 8 D
showed that the expression levels of wild-type and T668A
mutant APP were comparable in these cultures. However,
A  1-40 and 1-42 levels in neuronal cultures expressing
the T668A mutant APP were significantly reduced com-
pared with those expressing wild-type APP (Fig. 8 C).
These results suggest that phosphorylation of T668 regu-
lates APP processing and A  generation.
Discussion
T668 of APP has been shown to be phosphorylated in cells
undergoing mitosis and in cultured cortical neurons (Su-
zuki et al., 1994; Iijima et al., 2000). Here, we show that
phosphorylation of T668 is elevated in AD brain samples.
In AD brain sections, we observed the most prominent
P-APP signals in hippocampus. P-APP signal is associated
with dystrophic neurites surrounding the plaques, and
with enlarged endosomes primarily in the soma of hippo-
campal neurons. In addition, we found that most of the
neurons exhibiting P-APP–positive vesicles in the soma are
also positive for AT8 staining, an antibody specific for
phospho-Tau. Therefore, elevation of P-APP is specifically
present in the neuronal population afflicted in AD. We
have also surveyed human brain samples of other neurode-
generative diseases including Huntington’s disease, Parkin-
son’s disease, Progressive Supranuclear Palsy and Frontal
Temporal Dementia, and have not found significant ve-
sicular staining of P-APP (unpublished data). These ob-
servations suggest that the enrichment of the T668 phos-
phorylated APP in the enlarged endosomes is a pathology
specific to AD.
P-APP and BACE1 signals are enriched in enlarged 
endosomes in AD brains
It has been recently reported that the expression levels and
activities of BACE1 are up-regulated in AD brains, espe-
cially in neurons of temporal cortex and hippocampus (Fu-
kumoto et al., 2002; Holsinger et al., 2002). Interestingly,
we found that BACE1 signal is enriched in the enlarged
endosomes of hippocampal pyramidal neurons in AD
brain sections. Furthermore, BACE1 colocalizes with
P-APP in these enlarged endosomes. Analysis of AD brain
lysates reveals that phosphorylation of APP CTFs on T668
is up-regulated. In addition, we also found that the  CTFs
are preferentially phosphorylated on T668. Together, these
observations suggest that P-APP is preferentially cleaved by
the increased BACE1 in AD brain, possibly in the endo-
somes. Enhanced endocytic activity is one of the earliest
known neuropathological alternations in sporadic Alzhei-
mer’s disease. Abnormalities associated with the endocytic
pathway have been proposed to play a role in A  genera-
Figure 7.  CTFs are preferentially phosphorylated on T668. 
(A) Increasing amounts of  P-T668 was used to immunoprecipitate 
APP from lysates prepared from a 6-mo-old mouse brain. Western 
blot analysis using a pan APP antibody (C1/6.1) showed that increasing 
levels of  CTFs were efficiently precipitated by  P-T668, whereas 
little  CTFs were brought down by  P-T668 (top). Conversely, in the 
supernatants, a dose-dependent decrease of  CTFs but not  CTFs 
was observed. (B) The C1/6.1 antibody efficiently immunoprecipitated 
both  CTFs and  CTFs. In supernatants, both  CTFs and  CTFs 
were completely removed using 10  g of C1/6.1 antibody. 
(C) Quantification of the levels of  CTFs and  CTFs in supernatants 
from A and B reveals that  CTFs are efficiently removed from the 
brain lysates by  P-T668.T
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tion (Cataldo et al., 2000; Nixon et al., 2000). Recent
studies by Grbovic et al. (2003) demonstrated that A 
generation could be up-regulated by enhanced endocytic
activity as a result of overexpression of Rab5. As such, the
drastic up-regulation and accumulation of BACE1 and
P-APP in the endocytic vesicles implies the significance of
the enlarged endosomes in contributing to the altered pro-
cessing of APP in AD.
P-APP is preferentially associated with BACE1 in the 
endocytic pathway in primary cortical neurons
Endocytic pathway is one of the major sites where A  is nor-
mally generated (Nordstedt et al., 1993; Koo and Squazzo,
1994). The presence of APP in the Rab5-positive endocytic
compartments has been shown previously in rat brain nerve
terminals (Ikin et al., 1996). Here, we found that P-APP is
present in Rab5 labeled endocytic vesicles and exhibits
extensive colocalization with BACE1 in growth cones of
young cortical neurons. This observation is further sup-
ported by the coimmunoisolation of Rab5 with P-APP– and
BACE1-positive vesicles. In addition, P-APP and BACE1
cosegregate in the iodixanol gradient. In the gradient, the
fractionation profiles of P-APP and BACE1 largely overlap
with Rab5. As for older neurons, the colocalization of
P-APP and BACE1 is less prominent. Although endosomes
are highly enriched in the growth cones of young neurons,
endosomes of mature neurons are concentrated in branch re-
gion of axons and presynaptic nerve terminals (Overly and
Hollenbeck, 1996). Studies by Sabo et al. showed that APP
is localized in Rab5 containing synaptic organelles in mature
neurons (Sabo et al., 2003). It is possible that P-APP and
BACE1 colocalize in specific loci of neurites, such as areas
where synapses form in mature neurons.
Unlike the staining pattern of AD brains, we detected
modest colocalization of P-APP with the early endosome
marker EEA1, in primary cortical neurons. In the early en-
docytic pathway, Rab5 regulates both clathrin-coated vesi-
cle-mediated transport from the plasma membrane to the
early endosomes, as well as homotypic early endosome fu-
sion, whereas EEA1 medicates homotypic early endosome
fusion. Our findings suggest that in normal conditions,
P-APP is localized in Rab5-positive endocytic vesicles that
do not actively undergo homotypic endosome fusion. In ad-
dition, we did not observe extensive colocalization of P-APP
with recycling endosome marker Rab4 in primary cortical
neurons. It is likely that the colocalization of P-APP and
EEA1/Rab4 in AD brains is due to abnormalities in en-
docytic pathway associated with the disease state. We de-
tected little colocalization of P-APP with the TGN marker
adaptin-  and the cis-Golgi marker GM130. These observa-
tions suggest that P-APP is preferentially exposed to BACE1
in the Rab5-positive endosomes. Although BACE1 cleaves
APP in both the secretory pathway and endocytic compart-
ments, our results suggest that T668 phosphorylated APP is
likely the target of BACE1 in the Rab5-positive endocytic
compartments in both normal and disease conditions.
T668 phosphorylation regulates APP processing
A contribution of T668 phosphorylation on APP processing
is underscored by the significantly reduced A  1-40 and
1-42 secretion from neurons treated with T668 kinase inhib-
itors or neurons expressing the T668A mutant APP. In nor-
mal mouse brain lysates, the  CTF is much more abundant
than the  CTFs. Interestingly,  P-T668 preferentially rec-
ognizes  CTFs over  CTF and efficiently depletes  CTFs
from the brain lysates. This observation strongly suggests
Figure 8. Reduced A  generation by 
APP T668 to alanine mutant and T668 
kinase inhibitors in primary cortical 
neurons. (A) Inhibiting T668 phosphory-
lation by Cdk inhibitors leads to a 
decrease in A  secretion. Rat primary 
cortical neurons were treated with 
recombinant HSV expressing wild-type 
APP for 16 h and subsequently with 
indicated concentrations of roscovitine 
or butyrolactone for 8 h. The levels of 
secreted A  1-40 or A  1-42 were 
measured by sandwich ELISA and data 
were normalized against the untreated 
control. The data shown represent the 
average ( SEM) of three independent 
experiments. (**P   0.01; P   0.0051 
for A  1-40 and P   0.0071 for A  1-42 
under roscovitine treatment; and 
P   0.0054 for A  1-40 and P   0.0087 
for A  1-42 under butyrolactone 
treatment). (B) T668 phosphorylation 
levels of full-length APP were detected 
by Western blot of cell lysates. (C) A  
generation from rat primary cortical neurons expressing recombinant wild-type or T668A APP. Levels of A  1-40 and A  1-42 secreted into 
the media from virus infected cultures were measured by sandwich ELISA. Markedly reduced A  1-40 and A  1-42 were detected from 
neurons expressing the APP T668A mutant compared to those expressing wild-type APP. The data shown represent the average ( SEM) of 
three independent experiments with quadruple infections in each experiment. (** P   0.01 and *** P   0.001; and P   0.0001 for A  1-40 
and P   0.0027 for A  1-42). (D) Western blot analysis from four independent infections showed that the expression level of full-length APP 
was comparable between wild-type and T668A mutant APP.T
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that P-APP is more likely to be cleaved by the  -secretase.
Whether T668 phosphorylation of APP directly or indirectly
impacts on BACE1 cleavage remains to be determined.
We found that the T668A mutant produces 50% less A 
compared with the wild-type APP in cultured neurons. This
observation indicates that in the absence of T668 phosphor-
ylation, A  is still generated, albeit less efficiently. There-
fore, it is less likely that T668 phosphorylation directly im-
pacts on APP cleavage. Rather, T668 phosphorylation is
likely to be involved in the intracellular sorting and traffick-
ing of APP, which in turn impacts on the proteolytic cleav-
age of APP. This view is supported by the observation that
the T668A mutant is mislocalized as evident by its distribu-
tion in the heavier fractions of iodixanol gradient.
Previous studies by Ando et al. (2001) reported that T668
glutamate mutant of APP (T668E) did not affect A  gener-
ation in HEK293 cells. Unlike the T668E mutant, expres-
sion of the T668A mutant causes mislocalization of APP
and a decrease in A  generation. This, together with the ob-
servation that Cdk inhibitors roscovitine and butyrolactone
elicit the same effect as T668A mutant, strongly argues that
T668 phosphorylation of APP plays a role in regulating traf-
ficking of APP and A  generation.
From solution NMR studies, it has been predicted that
phosphorylation of T668 may result in a dramatic confor-
mational change of the APP cytoplasmic tail, which is likely
to affect the interaction of APP with its binding partners. In-
deed, Ando and colleagues showed that T668 phosphoryla-
tion weakens the interaction of APP with Fe65 (Ando et al.,
2001). However, the impact of the interactions of APP with
Fe65 on the metabolism of APP is less clear. Guenette et al.
(1996) and Sabo et al. (1999) reported that expressing Fe65
in MDCK and H4 neuroglioma cells lead to increased accu-
mulation of APP on the cell surface and increased secretion
of A . On the contrary, overexpression of Fe65 resulted in
reduced A  secretion in HEK293 cells (Ando et al., 2001).
As such, the effect of Fe65 appears to be cell-type specific. It
is possible that disruption of the APP–Fe65 interaction
through phosphorylation of T668 represents one of the
mechanisms underlying increased generation of A .
When considered together, our findings that T668 phos-
phorylation facilitates APP and BACE1 colocalization and
that inhibition of T668 phosphorylation decreases A  gen-
eration suggest that T668 phosphorylation of APP is a mo-
lecular mechanism regulating its cleavage by BACE1. As
BACE1 cleavage is the essential step for A  generation, un-
derstanding how proteolysis by BACE1 is regulated will help
elucidate the intricate intracellular signaling network regu-
lating the generation of A .
Materials and methods
DNA constructs
GST fusion protein of cytoplasmic domain of APP (residues 649–695) was
constructed by PCR and cloned into the bacterial expression vector pGEX-
4T2 (Amersham Biosciences). The APP T668A and T668E constructs were
generated via PCR using complementary primers as described previously
(Niethammer et al., 2000).
Antibodies
Anti-APP (C1/6.1) was a gift from R.A. Nixon and P.M. Mathews (both
from Nathan Kline Institute, Orangeburg, NY). 4G8 was obtained from
Senetek. AT8 was obtained from Innogenetics. Anti-BACE1 was obtained
from Oncogene Research Products and Calbiochem. Anti-Rab5 and anti-
Bip were obtained from StressGen Biotechnologies. Anti-Rab4, anti-Rab7,
and anti–cathepsin D were obtained from Santa Cruz Biotechnology, Inc.
Anti–adaptin-  and anti-GM130 were obtained from BD Biosciences.
Anti-PS1 mAbs and pAbs were obtained from CHEMICON International,
Inc. and a gift from D. Selkoe (Harvard Medical School). Anti-SV2 and
anti–cathepsin   were gifts from K.M. Buckley and H.L. Ploegh, respec-
tively (both from Harvard Medical School).
Generation of  P-T668
The phospho-epitope–specific APP antibody was generated against a syn-
thetic peptide antigen corresponding to APP phosphorylated at the T668
residue: VDAAVpTPEERHC, where pT denotes phosphothreonine (Tufts
Peptide Synthesis Core Facility). The peptide was conjugated to KLH with
sulfo-MBS (Pierce Chemical Co.) and injected into NZW rabbits (Covance
Research Products Inc.). The antiserum was first adsorbed against a corre-
sponding nonphosphorylated peptide, VDAAVTPEERHC, and purified
with the phospho-peptide coupled to a SulfoLink coupling column (Pierce
Chemical Co.).
Cell line and neuronal cell culture
Catecholaminergic cell lines (CAD cells) were cultured in DME supple-
mented with 10% FBS and L-glutamine in a humidified 5% CO2 incubator.
Primary cultures of embryonic rat cortical neurons were prepared as de-
scribed previously (Niethammer et al., 2000). In brief, dissociated embry-
onic neurons from E18 Sprague-Dawley pregnant rats were plated onto
poly-D-lysine/laminin–coated 24-well plates or coverslips and maintained
in neurobasal medium (Invitrogen) supplemented with B27 (Invitrogen),
L-glutamine (Sigma-Aldrich) and 1% penicillin-streptomycin sulfate.
Generation of recombinant HSV
Wild-type and T668A APP coding sequence were subcloned into a repli-
cation-defective HSV vector pHSVPrpUC. The resultant recombinant plas-
mid was packaged into virus particles in the packaging line 2–2 using the
protocol described previously (Lim et al., 1996). The virus was then puri-
fied on a sucrose gradient, pelleted, and resuspended in 10% sucrose and
the titer of the recombinant virus was determined.
Immunohistochemistry
AD and control tissues were obtained from the autopsy service at
Brigham and Women’s Hospital. Neuropathological diagnosis of AD was
confirmed according to the criteria of Khachaturian (1985). Blocks of AD
or control hippocampi were fixed (1–48 h) in 10% neutral buffered for-
malin. After fixation, the brain tissue was dehydrated and embedded in
paraffin. 20 micrometer serial sections were cut, dried, and baked at
60 C for 1 h. Serial sections were immunostained using the avidin-biotin
HFP/DAB method (Vector Laboratories) or by immunofluorescence. De-
tails of the immunostaining protocol have been described previously
(Lemere et al., 1996). All images were captured using an inverted micro-
scope (Nikon) linked to a DeltaVision deconvolution imaging system (Ap-
plied Biosystems). For some immunofluorescence staining, the primary
antibody was directly labeled with Oregon green using the FluoReporter
Oregon green 488 protein labeling kit (Molecular Probes) according to
manufacturer’s specifications.
For the peptide preadsorption experiment, antibodies were mixed with
peptides at a 1:100 molar ratio and incubated overnight at 4 C before be-
ing used for staining.
Immunocytochemistry
Primary cortical neurons from E18 rat embryos were cultured at a density
of 10
5 cells/well in 24-well plates. 2 d after plating, neurons were fixed in
4% PFA for 30 min, blocked, and permeabilized in 10% normal goat se-
rum and 0.1% Triton in PBS for 20 min. Permeabilized neurons were incu-
bated with primary antibodies for 1 h at room temperature, and subse-
quently incubated with Oregon green– or Texas red–conjugated secondary
antibodies (Molecular Probes). Images were captured using an inverted mi-
croscope (Nikon) linked to a DeltaVision deconvolution imaging system
(Applied Biosystems).
Immunodepletion
Immunodepletion was performed by lysing the mouse brain in RIPA buffer
(50 mM Tris, pH 8.0, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS,
150 mM NaCl, and protease and phosphatase inhibitors [1 mM PMSF, 1
 g/ml aprotinin and leupeptin, and 20 mM  -glycerol phosphate]) using a
Dounce homogenizer. The lysates were centrifuged at 13,000 rpm for 15T
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min at 4 C. 300  g of lysates were incubated with indicated amounts of
antibodies and 30  l of 50% slurry of protein A–Sepharose (Amersham
Biosciences) at 4 C for 2.5
 h. The immunoprecipitates were washed three
times with RIPA buffer, resuspended in Laemmli sample buffer, and ana-
lyzed by Western blot analysis.
Immunoisolation
Adult mouse brain was homogenized in 2 ml of immunoisolation buffer
(250 mM sucrose, 20 mM Hepes, pH 7.3, 5 mM MgCl2,, and protease and
phosphatase inhibitors) by 20 strokes in a Dounce homogenizer followed
by an additional 20 strokes in a 1-ml syringe fitted with 21-gauge needle.
Lysates were centrifuged at 3,000 rpm for 15 min. The postnuclear super-
natant (PNS) was collected and centrifuged at 27,000 rpm for 30 min to
precipitate vesicles. The resulting pellet was resuspended in immunoisola-
tion buffer that did not contain sucrose. Equal amounts of vesicle suspen-
sion were incubated at 4 C overnight with indicated antibody that had
been preconjugated to M-280 Tosylactivated Dynabeads (Dynal) accord-
ing to the manufacturer’s instructions. Immunoisolates were washed three
times with immunoisolation buffer containing 0.1% BSA, resuspended in
Laemmli sample buffer, and subjected to Western blot analysis.
Mass spectrometric analysis
Blocks of AD hippocampi (gifts from M. Frosch, Massachusetts General
Hospital, Boston, MA) were lysed in RIPA buffer using a Dounce homog-
enizer. T668 phosphorylated APP were isolated using a  P-T668 column
according to the manufacturer’s instructions (Amersham Biosciences).
Isolated proteins were resolved using SDS-PAGE. Protein bands contain-
ing APP-CTFs were cut and subjected to S-carbamidomethylation and in-
gel trypsin digestion (Stensballe and Jensen, 2001). Peptide digests were
extracted in 25 mM ammonium bicarbonate, pH 8.8, containing 25%
(vol/vol) dimethyl foramide and further purified using ZipTipC18 (Milli-
pore). Purified peptides were mixed with  –cyano-4-hydroxycinnamic
acid matrix and analyzed by Voyager DE-STR mass spectrometer (PerSep-
tive Biosystems). Postsource decay experiments were performed accord-
ing to the protocols provided the manufacturer. Tables of mass/charge
(m/z) of trypsinized APP peptides were generated using Protein Prospec-
tor (http://prospector.ucsf.edu/). The tolerance of the difference between
experimental and theoretical m/z values in comparison was constrained
under 300 ppm.
Iodixonal step gradient
Half of a 1-mo-old adult mouse brain was homogenized in 1 ml of homog-
enization buffer (HB: 250 mM sucrose, 20 mM Tris-HCl, pH 7.4, 1 mM
EGTA, 1 mM EDTA, and protease and phosphatase inhibitors) by 20
strokes in a Dounce homogenizer followed by an additional 20 strokes in
a 1-ml syringe fitted with 21-gauge needle. Lysates were centrifuged at
3,000 rpm for 15 min to generate the PNS. The PNS was then adjusted to
25% OptiPrep (Nycomed/Axis-Shield PoC.) with 50% OptiPrep in HB. The
resulting mixture, 2 ml in 25% OptiPrep, was placed at the bottom of an
ultracentrifuge tube (14   89 mm) and was overlaid successively with 1
ml each of 20, 18.5, 16.5, 14.5, 12.5, 10.5, 8.5, 6.5, and 5% OptiPrep in
cold HB. The gradients were centrifuged for 20 h at 27,000 rpm at 4 C in a
rotor (model SW41; Beckman Coulter). 500 l fractions were collected
from the top of the ultracentrifuge tubes and analyzed by Western blot
analysis. P-APP, APP, and BACE levels in each fraction were digitized by a
Luminescent Image Analyzer (Fujifilm) and expressed as a percentage of
the sum of all of the fractions.
A  measurement by ELISA assay
T668 kinase inhibitor.  Primary cortical neurons were cultured from E18 rat
embryos at a density of 4   10
5 cells/well in 24-well plates. 2 d after plat-
ing, neurons were infected with recombinant HSV expressing wild-type
APP for 16 h. Subsequently, 70% of culture media was replaced with fresh
medium and neurons were treated with indicated concentration of Rosco-
vitine or Butyrolactone. 8 h after inhibitor treatment, culture media was
collected and subjected to sandwich ELISA assay according to the manu-
facturer’s specifications (Biosource International). 
T668A mutant.  Primary cortical neurons from E18 rat embryos were cul-
tured at a density of 2   10
5 cells/well in 24-well plates. 2 d after plating,
70% of culture media was replaced with fresh medium. Neurons were
subsequently infected with equal titer of HSV expressing either wild-type
or T668A APP. 20 h after infection, culture media was collected and sub-
jected to sandwich ELISA assay. We observed most dramatic effect on A 
generation 24 h after infection. By 48 h after infection, the effect is less
pronounced. Data were analyzed by t test using Prism (GraphPad). Differ-
ences were considered significant at P   0.05.
Online supplemental material
The supplemental material (Figs. S1–S6 and Tables S1 and S2) is available
at http://www.jcb.org/cgi/content/full/jcb.200301115/DC1. Fig. S1 shows
characterization of  P-T668. Fig. S2 shows additional controls for  P-T668
staining of AD brain sections and that  P-T668 labels dystrophic neurites
closely associated with amyloid plaques in APPswe Tg mice. Fig. S3 shows
a partial MALDI-TOF MS spectrum of APP CTFs from CAD cells overex-
pressing human APP. Figs. S4 and S5 show costaining of P-APP and or-
ganelle markers in AD brain sections and in rat primary cortical neurons.
Fig S6 shows distribution of wild-type, T668A mutant APP, and BACE1
from cultured cortical neurons in iodixanol step gradient. Tables S1 and S2
show case information of human brains analyzed by immunohistochemis-
try and Western blot analysis.
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